5 completed, 3 terminated, 2 recruiting, 1 enrolling by invitation. 13 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 5, Terminated 3, Recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 6 | Completed 2, Recruiting 2, Not yet recruiting 1, Unknown 1 |
Follow T Cell Lymphoma: new trials by email Literature Review of T Cell Lymphoma trials Research Report on T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies HY035 cell injection - Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 13 | 2026-08-15 | 2026-08-25 |
| CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation CD7 CAR-T combined with autologous hematopoietic stem cell transplantation - CD7+ Lymphoma, T Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Zhengzhou University | 38 | 2025-09-01 | 2025-08-12 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-04-03 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) ACHOP - T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Won Seog Kim | 41 | 2022-07-01 | 2023-10-23 |
| Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma chimeric antigen receptor T cell treatment - T Cell Lymphoma, T-cell Leukemia | Phase 1 | Completed | Beijing Boren Hospital | 16 | 2021-09-14 | 2024-11-14 |
| LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Efficacy of LCAR-T2C CAR-T cells - T Cell Lymphoma, T-cell Leukemia | Phase 1 | Terminated | Beijing Boren Hospital | 9 | 2021-07-02 | 2022-08-16 |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. HSP-CAR30 - Hodgkin Lymphoma, Adult, T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 30 | 2020-09-29 | 2020-12-04 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) CTX130 - T Cell Lymphoma | Phase 1 | Terminated | CRISPR Therapeutics AG | 49 | 2020-07-31 | 2025-01-08 |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Tenalisib, Romidepsin - T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Rhizen Pharmaceuticals SA | 33 | 2019-03-12 | 2022-10-28 |
| AMG 319 Lymphoid Malignancy FIH AMG 319 - Cancer, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Amgen | 28 | 2011-04-01 | 2017-02-09 |
| A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Sorafenib - T Cell Lymphoma | Phase 1 | Completed | Yale University | 12 | 2009-10-01 | 2020-08-13 |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Poly-ICLC - B Cell Lymphoma, T Cell Lymphoma | Phase 1 | Terminated | Nevada Cancer Institute | 3 | 2009-04-01 | 2011-07-20 |
Lymphoma, T-Cell (13) · Leukemia (3) · Leukemia, T-Cell (3) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13) · Neoplasms by Histologic Type (13) · Lymphoma, Non-Hodgkin (12) · Neoplasms (12) · Lymphoma (11) · Hematologic Diseases (6) · Leukemia, Lymphoid (5) · Leukemia (3) · Disease Attributes (2) · Leukemia, Myeloid (2) · Pathologic Processes (2)
N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (1) · Sorafenib (1) · poly ICLC (1) · romidepsin (1) · tenalisib (1)
Beijing Boren Hospital (2) · Amgen (1) · CRISPR Therapeutics (1) · CRISPR Therapeutics AG (1) · Essen Biotech (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Nevada Cancer Institute (1) · Rhizen Pharmaceuticals SA (1) · Won Seog Kim (1) · Yale University (1) · Zhengzhou University (1)
United States (6) · China (5) · Australia (2) · Canada (1) · South Korea (1) · Spain (1)
Alissa Keegan, MD, PhD (1) · Alissa Keegan, PhD (1) · Delva Deauna-Limayo, MD (1) · Francine Foss, MD (1) · Kai Hu, MD/PhD (1)